跳至主要内容
临床试验/EUCTR2018-004853-26-FI
EUCTR2018-004853-26-FI进行中(未招募)1 期

The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer

Turku University Hospital0 个研究点目标入组 35 人开始时间: 2019年3月7日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • -Age: 40 to 85 years old
  • -Language spoken: Finnish
  • -Diagnosis: Histologically confirmed adenocarcinoma of prostate
  • -Adequate histological sampling consisting of at least 3 biopsy samples from each lobe
  • -No previous surgical, radiation or endocrine treatment for prostate carcinoma
  • -Clinical stage:
  • -T1c-T4NanyM1
  • -Serum creatinine = 1,5 x ULN
  • -Mental status: Patients must be able to understand the meaning of the study
  • -Informed consent: The patient must sign the appropriate Ethical Committee approved informed consent documents in the presence of the
  • designated staff
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 5
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • -Previous PC treatment
  • -Uncontrolled serious infection
  • -Prior usage of 5-ARI medication in past 12 months

研究者

相似试验